Abstract 1935: Racial and ethnic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy: A National Cancer Database analysis

Abstract Purpose: To evaluate the association between race and ethnicity and all-cause mortality among women with advanced-stage ovarian cancer who received systemic therapy. Methods: We obtained data from the National Cancer Database on women diagnosed with advanced-stage ovarian cancer from 2004 to 2015. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) by race and ethnicity groups (non-Hispanic (NH)-White, NH-Black, Hispanic, NH-Asian/Pacific Islander, and Other) and to examine the association of race/ethnicity with survival, stratified by age and comorbidity while adjusting for clinical and demographic variables. Results: There were 53,367 women (52.4% ages ≥ 65 years, 8.7% NH-Black, 5.7% Hispanic, and 2.7% NH-Asian/Pacific Islander) included in the analysis. NH-Black women had a higher risk of death compared to NH-White women (HR: 1.13; 95% CI: 1.07,1.18), while Hispanic women had a lower risk of death compared to NH-White women (HR: 0.89; 95% CI: 0.82,0.97). The Black-White disparity persisted for women ages < 65 years and ≥ 65 years, and among women with no comorbidities (HR:1.14; 95% CI: 1.08,1.21). Conclusion: Among women with advanced-stage ovarian cancer who received systemic therapy, NH-Black women experienced decreased survival compared with NH-White women, regardless of age and comorbidity status. Additional research is essential to identify drivers of ovarian cancer disparities, including racial differences in treatment response. Citation Format: Caretia J. Washington, Shama D. Karanth, Dejana Braithwaite, Tomi F. Akinyemiju. Racial and ethnic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy: A National Cancer Database analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1935.